ROS1 fusions are recognized as actionable oncogenic alterations underlying the carcinogenesis of non-small cell lung cancer (NSCLC), occurring in approximately 1%–2% of NSCLC patients (Drilon et al., 2021). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.